Search Site

Search form

Archived Press Releases

All Releases
View Summary Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation
May 12, 2015
PDF 11.3 KB
View Summary Vertex Reports First Quarter 2015 Financial Results
Apr 29, 2015
PDF 39.8 KB
View Summary Vertex to Announce First Quarter 2015 Financial Results on April 29
Apr 9, 2015
PDF 6.8 KB
View Summary Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Mar 23, 2015
PDF 27.6 KB
View Summary Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene
Mar 18, 2015
PDF 19.6 KB
View Summary Vertex to Present at Upcoming Investor Conferences
Feb 11, 2015
PDF 7.0 KB
View Summary Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015
Jan 28, 2015
PDF 58.5 KB
View Summary Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis
Jan 11, 2015
PDF 30.2 KB
View Summary Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results
Jan 6, 2015
PDF 7.2 KB
View Summary U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
Dec 29, 2014
PDF 19.6 KB
View Summary David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer
Dec 15, 2014
PDF 10.6 KB
View Summary Vertex to Present at Deutsche Bank BioFEST on December 2
Nov 20, 2014
PDF 6.9 KB
View Summary Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Nov 5, 2014
PDF 14.5 KB
View Summary Vertex to Present at the Credit Suisse Healthcare Conference on November 11
Oct 30, 2014
PDF 6.9 KB
View Summary Vertex Reports Third Quarter 2014 Financial Results
Oct 28, 2014
PDF 61.9 KB
View Summary FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
Oct 21, 2014
PDF 19.3 KB
View Summary Vertex to Announce Third Quarter 2014 Financial Results on October 28
Oct 14, 2014
PDF 6.8 KB
View Summary Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis
Oct 9, 2014
PDF 70.1 KB
View Summary Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014
Sep 8, 2014
PDF 67.0 KB
View Summary Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10
Sep 2, 2014
PDF 6.8 KB
Showing 41-60 of 275 Page: 1 2 3 4 5 6 7 ... 14  Previous 20 | Next 20